Baillie Gifford & Co’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $109M | Buy |
1,208,945
+768,737
| +175% | +$64.4M | 0.1% | 129 |
|
|
2026
Q1 | $35.3M | Sell |
440,208
-76,103
| -15% | -$6.27M | 0.04% | 161 |
|
|
2025
Q4 | $44M | Sell |
516,311
-55,936
| -10% | -$4.59M | 0.04% | 154 |
|
|
2025
Q3 | $44.5M | Sell |
572,247
-10,351
| -2% | -$809K | 0.03% | 161 |
|
|
2025
Q2 | $45.6M | Buy |
582,598
+1,157
| +0.2% | +$86.3K | 0.03% | 154 |
|
|
2025
Q1 | $42.1M | Sell |
581,441
-125,355
| -18% | -$8.97M | 0.04% | 150 |
|
|
2024
Q4 | $52.3M | Buy |
706,796
+498,100
| +239% | +$34.9M | 0.04% | 143 |
|
|
2024
Q3 | $13.8M | Sell |
208,696
-143,607
| -41% | -$10.4M | 0.01% | 197 |
|
|
2024
Q2 | $32.5M | Sell |
352,303
-44,250
| -11% | -$3.92M | 0.03% | 159 |
|
|
2024
Q1 | $37.9M | Sell |
396,553
-7,405
| -2% | -$622K | 0.03% | 162 |
|
|
2023
Q4 | $30.8M | Sell |
403,958
-36,443
| -8% | -$2.54M | 0.02% | 175 |
|
|
2023
Q3 | $30.5M | Sell |
440,401
-23,639
| -5% | -$1.9M | 0.03% | 169 |
|
|
2023
Q2 | $43.8M | Sell |
464,040
-3,444
| -0.7% | -$299K | 0.04% | 158 |
|
|
2023
Q1 | $38.7M | Buy |
467,484
+31,993
| +7% | +$2.51M | 0.03% | 158 |
|
|
2022
Q4 | $32.5M | Buy |
435,491
+3,345
| +0.8% | +$258K | 0.03% | 166 |
|
|
2022
Q3 | $35.7M | Buy |
432,146
+11,921
| +3% | +$1.15M | 0.04% | 158 |
|
|
2022
Q2 | $40M | Sell |
420,225
-5,000
| -1% | -$518K | 0.04% | 164 |
|
|
2022
Q1 | $50.1M | Sell |
425,225
-7,463
| -2% | -$837K | 0.04% | 174 |
|
|
2021
Q4 | $56.1M | Buy |
432,688
+11,143
| +3% | +$1.3M | 0.03% | 176 |
|
|
2021
Q3 | $47.7M | Buy |
421,545
+17,758
| +4% | +$2.03M | 0.03% | 186 |
|
|
2021
Q2 | $41.8M | Sell |
403,787
-1,170
| -0.3% | -$110K | 0.02% | 200 |
|
|
2021
Q1 | $33.9M | Buy |
404,957
+124,646
| +44% | +$10.5M | 0.02% | 204 |
|
|
2020
Q4 | $25.6M | Buy |
280,311
+26,830
| +11% | +$2.23M | 0.01% | 190 |
|
|
2020
Q3 | $20.2M | Buy |
253,481
+58,738
| +30% | +$4.58M | 0.01% | 182 |
|
|
2020
Q2 | $13.5M | Buy |
194,743
+191,332
| +5,609% | +$13.6M | 0.01% | 186 |
|
|
2020
Q1 | $214K | Sell |
3,411
-357
| -9% | -$25.7K | ﹤0.01% | 211 |
|
|
2019
Q4 | $293K | Hold |
3,768
| – | – | ﹤0.01% | 212 |
|
|
2019
Q3 | $276K | Sell |
3,768
-213
| -5% | -$15K | ﹤0.01% | 213 |
|
|
2019
Q2 | $245K | Hold |
3,981
| – | – | ﹤0.01% | 220 |
|
|
2019
Q1 | $254K | Hold |
3,981
| – | – | ﹤0.01% | 220 |
|
|
2018
Q4 | $203K | Buy |
+3,981
| New | +$201K | ﹤0.01% | 219 |
|
Other funds holding EW
Baillie Gifford & Co's EW Position: Q2 2026 in Review
Baillie Gifford & Co increased its Edwards Lifesciences (EW) stake by 175% in Q2 2026, buying an estimated $64.4M and bringing the position to 1,208,945 shares worth $109M. The position accounts for 0.1% of the portfolio, ranked #129.
Baillie Gifford & Co first reported a position in EW in Q4 2018 and has held it in 31 quarters since. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Baillie Gifford & Co held 1,208,945 shares of Edwards Lifesciences worth $109M as of Q2 2026.
- Baillie Gifford & Co bought 768,737 Edwards Lifesciences shares in Q2 2026, an estimated $64.4M.
- Edwards Lifesciences made up 0.1% of Baillie Gifford & Co's portfolio in Q2 2026, its #129 holding.
- Baillie Gifford & Co first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 31 quarters since.
- 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.